Atlas Trials

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Clinical trial NCT05581823 · COMPLETED

Trial details

NCT number
NCT05581823
Sponsor
Cerevel Therapeutics, LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Parkinson Disease
Start date
2022-10-19
Primary completion
2023-01-27
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.